Rivaroxaban for the treatment of venous thromboembolism in pediatric patients

References

• Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines [published correction appears in Chest. 2014 Dec;146(6):1694. Dosage error in article text] [published correction appears in Chest. 2014 Nov;146(5):1422]. Chest. 2012;141(2 Suppl):e737S–e801S.
   PubMed Web of Science ®Google Scholar
• Levy-Mendelovich S, Barg AA, Kenet G. Thrombosis in pediatric patients with leukemia. Thromb Res. 2018;164(Suppl 1):S94–7.
   PubMedGoogle Scholar
• Kenet G, Limperger V, Shneyder M, et al. Risk factors for symptomatic venous and arterial thromboembolism in newborns, children and adolescents - What did we learn within the last 20years? Blood Cells Mol Dis. 2017;67:18–22. .
   PubMed Web of Science ®Google Scholar
• Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83(5):1251–1257.
   PubMed Web of Science ®Google Scholar
• Massicotte MP, Dix D, Monagle P, et al. Central venous catheter related thrombosis in children: analysis of the Canadian registry of venous thromboembolic complications. J Pediatr. 1998;133(6):770–776.
   PubMed Web of Science ®Google Scholar
• Van Ommen CH, Heijboer H, Büller HR, et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr. 2001;139(5):676–681.
   PubMed Web of Science ®Google Scholar
• Kenet G, Cohen O, Bajorat T, et al. Insights into neonatal thrombosis. Thromb Res. 2019;181(Suppl 1):S33–6.
   PubMedGoogle Scholar
• Young G. How I treat pediatric venous thromboembolism. Blood. 2017;130(12):1402–1408.
   PubMed Web of Science ®Google Scholar
• Perzborn E, Roehrig S, Straub A, et al. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011;10(1):61–75.
   PubMed Web of Science ®Google Scholar
• Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th Edition) [published correction appears in Chest. 2008 Aug;134(2):473]. Chest. 2008;133(6Suppl):141S–59S.
   PubMedGoogle Scholar
• Klein TE, Altman RB, Eriksson N, et al. International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data [published correction appears in N Engl J Med. 2009 Oct 15;361(16):1613. Dosage error in article text]. N Engl J Med. 2009;360(8):753–764.
   PubMed Web of Science ®Google Scholar
• Leadley RJ Jr. Coagulation factor Xa inhibition: biological background and rationale. Curr Top Med Chem. 2001;1(2):151–159.
   PubMedGoogle Scholar
• Tuszynski GP, Gasic TB, Gasic GJ. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation. J Biol Chem. 1987;262(20):9718–9723.
   PubMed Web of Science ®Google Scholar
• Waxman L, Smith DE, Arcuri KE, et al. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa [published correction appears in Science 1990 Jun 22;248(4962):1473]. Science. 1990;248(4955):593–596.
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost. 2007;5(4):886–888.
   PubMed Web of Science ®Google Scholar
• Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-([(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl]methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct Factor Xa inhibitor. J Med Chem. 2005;48:5900–5908.
   PubMed Web of Science ®Google Scholar
• Samama MM. The mechanism of action of rivaroxaban—an oral, direct Factor Xa inhibitor—compared with other anticoagulants. Thromb Res. 2011;127:497–504.
   PubMed Web of Science ®Google Scholar
• Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3:514–521.
   PubMed Web of Science ®Google Scholar
• Mueck W, Stampfuss J, Kubitza D, et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1‐16.
   PubMed Web of Science ®Google Scholar
• Samama MM. Which test to measure the anticoagulant effect of rivaroxaban: the anti-Factor Xa assay. J Thromb Haemost. 2013;11:579–580.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Pasalic L, Curnow J, et al. Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges. Curr Drug Metab. 2017;18(7):598–608.
   PubMed Web of Science ®Google Scholar
• Douxfils J, Ageno W, Samama CM, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16(2):209–219.
   PubMed Web of Science ®Google Scholar
• Kubitza D, Willmann S, Becka M, et al. Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. Thromb J. 2018;16:31. Published 2018 Dec 4. .
   PubMed Web of Science ®Google Scholar
• Monagle P, Lensing AWA, Thelen K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019;6(10):e500‐9.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–1167.
   PubMed Web of Science ®Google Scholar
• Young G, Lensing AWA, Monagle P, et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020;18(7):1672-1685. doi:https://doi.org/10.1111/jth.14813.
   Google Scholar
• Chhim RF, Shelton CM, Christensen ML. Recent new drug approvals, part 2: drugs undergoing active clinical studies in children. J Pediatr Pharmacol Ther. 2013;18(1):14–38.
   PubMedGoogle Scholar
• Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211‐22. .
   Web of Science ®Google Scholar
• Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2Suppl):e278S‐e325S.
   Google Scholar
• Anderson DR, Morgano GP, Bennett C, et al. American society of hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019;3(23):3898‐944.
   Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765‐75.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31–39.
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776‐86.
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673–1680.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation. 2007;116(2):180‐7.
   Web of Science ®Google Scholar
• Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood. 2008;112(6):2242‐7.
   Web of Science ®Google Scholar
• Cohen AT, Bauersachs R. Rivaroxaban and the EINSTEIN clinical trial programme. Blood Coagul Fibrinolysis. 2019;30(3):85–95.
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499‐510.
   Web of Science ®Google Scholar
• Büller HR, Prins MH, Lensin AWA, et al. EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287‐97.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report [published correction appears in Chest. 2016 Oct;150(4):988]. Chest. 2016;149(2):315–352.
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017‐23.
   Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615‐24.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1891‐94.
   Web of Science ®Google Scholar
• Zimetbaum P. Atrial Fibrillation [published correction appears in Ann Intern Med. 2017 Jun 20;166(12):920]. Ann Intern Med. 2017;166(5):ITC33–48.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883‐91.
   Web of Science ®Google Scholar
• Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF) [published correction appears in Circulation. 2018 Dec 18;138(25):e783]. Circulation. 2014;130(2):138‐46.
   Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319‐30.
   Web of Science ®Google Scholar
• Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219‐29.
   Web of Science ®Google Scholar
• Branch KR, Probstfield JL, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. Circulation. 2019;140(7):529‐37.
   PubMed Web of Science ®Google Scholar
• Chan A, Lensing AWA, Kubitza D, et al. Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis. Thromb J. 2018;16:29. Published 2018 Nov 1. .
   PubMed Web of Science ®Google Scholar
• Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020;7(1):e18–27.
   PubMed Web of Science ®Google Scholar
• Pina LM, Dong X, Zhang L, et al. Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: rationale and design of a prospective, randomized trial (the UNIVERSE study). Am Heart J. 2019;213:97–104.
   PubMed Web of Science ®Google Scholar
• Monagle P, Cochrane A, Roberts R, et al. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. J Am Coll Cardiol. 2011;58(6):645–651.
   PubMed Web of Science ®Google Scholar
• Menon N, Sarode R, Zia A. Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis. Blood Adv. 2018;2(2):142–145.
   PubMed Web of Science ®Google Scholar
• Martinelli I, Bucciarelli P, Artoni A, et al. Anticoagulant treatment with rivaroxaban in severe protein S deficiency. Pediatrics. 2013;132(5):e1435–39.
   PubMed Web of Science ®Google Scholar
• Van Bruwaene L, Huisman A, Urbanus RT, et al. Heparin-resistant thrombosis due to homozygous antithrombin deficiency treated with rivaroxaban: a case report. J Pediatr Hematol Oncol. 2016;38(8):658–660.
   PubMed Web of Science ®Google Scholar
• Sartori M, Favaretto E, Cini M, et al. Rivaroxaban in the treatment of heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2015;40(3):392–394.
   PubMed Web of Science ®Google Scholar
• Pollak U, Mishaly D, Kenet G, et al. Heparin-induced thrombocytopenia complicating children after the Fontan procedure: single-center experience and review of the literature. Congenit Heart Dis. 2018;13(1):16–25.
   PubMed Web of Science ®Google Scholar
• Obeng EA, Harney KM, Moniz T, et al. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system. J Pediatr. 2015;166(1):144–150.
   PubMed Web of Science ®Google Scholar
• Pollak U. Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support in pediatric patients: review of the literature and alternative anticoagulants. Perfusion. 2018;33(1_suppl):7–17.
   PubMedGoogle Scholar
• Cuker A, Arepally GM, Chong BH, et al. American society of hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360–3392.
   PubMed Web of Science ®Google Scholar
• Casan JM, Grigoriadis G, Chan N, et al. Rivaroxaban in treatment refractory heparin-induced thrombocytopenia. BMJ Case Rep. 2016;2016:bcr2016216110. Published 2016 Aug 12. .
   PubMedGoogle Scholar
• Samoš M, Bolek T, Ivanková J, et al. Heparin-induced thrombocytopenia presenting with deep venous thrombosis and pulmonary embolism successfully treated with rivaroxaban: clinical case report and review of current experiences. J Cardiovasc Pharmacol. 2016;68(5):391–394.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017;130(9):1104–1113.
   PubMed Web of Science ®Google Scholar
• Linkins LA, Warkentin TE, Pai M, et al. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. J Thromb Haemost. 2016;14(6):1206–1210.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang H, Zhang J, et al. Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: A pilot study. Exp Ther Med. 2018;15(1):739–744.
   PubMed Web of Science ®Google Scholar
• Sexton DJ, de Freitas DG, Little MA, et al. Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome. Kidney Int Rep. 2018 3;(4):784–793. Published 2018 Mar 3. doi:https://doi.org/10.1016/j.ekir.2018.02.010.
   Google Scholar